Source: NuGen.
  • Common shares of NuGen Medical Devices (NGMD) have begun trading on the OTCQB under the symbol NGMDF
  • The company’s common shares will continue to trade on the TSX Venture Exchange under the symbol NGMD
  • Trading on the OTCQB will provide NuGen with added visibility to U.S. investors
  • The company also reports that it is awaiting approval for its application for DTC eligibility
  • NuGen is a specialty medical device company
  • NuGen Medical Devices (NGMD) is up 9.52 per cent on the day, trading at C$0.115 per share at 1:30 pm ET

Common shares of NuGen Medical Devices (NGMD) have begun trading on the OTCQB under the symbol NGMDF.

The company’s common shares will continue to trade on the TSX Venture Exchange under the symbol NGMD.

“Commencing trading on the OTCQB venture exchange is an important milestone for NuGen,” stated Michael Wright, CEO of NuGen.

“Having our common shares available on the OTCQB will increase accessibility for American investors interested in directly participating in NuGen’s growth with the same ease as their Canadian counterparts.”

The OTCQB Venture Market is for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their financial reporting and undergo an annual verification and management certification process.

The company also reports that it is awaiting approval for its application for DTC eligibility for electronic settlement and transfer of its common shares in the United States.

NuGen is a specialty medical device company developing needle-free technologies and other innovative medical delivery products.

NuGen Medical Devices (NGMD) is up 9.52 per cent on the day, trading at C$0.115 per share at 1:30 pm ET.


More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.